YOLFTbeta
LENZ Therapeutics Inc

LENZ Therapeutics Inc

LENZ · NASDAQ · Healthcare / Biotechnology

4.13USD+0.04 (+0.98%)

Price History

Full chart

Market Stats

Previous Close4.09
Open4.06
Day Range3.91 – 4.17
52-Week Range3.60 – 50.40
Volume748.57K
Market Cap124.42M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.18
Dividend Yield0.00%
Beta1.63
50-Day Avg4.90
200-Day Avg9.69

About

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Evert B. Schimmelpennink
  • Employees152
  • Headquarters201 Lomas Santa Fe Drive, Solana Beach, CA, United States, 92075, USA
  • Websitehttps://www.lenz-tx.com

Leadership

  • Mr. Evert B. SchimmelpenninkPresident, CEO, Secretary & Director · b. 1972
  • Mr. James W. McCollumCo-Founder & Director · b. 1955
  • Mr. Shawn OlssonChief Commercial Officer · b. 1983
  • Mr. Marc G. Odrich M.D.Chief Medical Officer · b. 1959
  • Mr. Daniel R. Chevallard CPAChief Financial Officer · b. 1980
  • Mr. Domenick PorfidiaVice President of Sales
  • Mr. David ChoromanskiVice President of Marketing
  • Ms. Melissa RosnessSenior Vice President of Manufacturing Operations
  • Kris GambelinSenior Vice President of Regulatory & Clincal Operations

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--015.00M0019.09M
Growth (%)-----100.00%--
Cost of Revenue-121.00K734.00K8.35M2.41M58.00K705.00K
Gross Profit--121.00K-734.00K15.00M-2.41M-58.00K18.38M
Gross Margin---100.00%--96.31%
Operating Expense-13.38M59.71M25.48M70.02M58.55M109.52M
Operating Income-29.00K-13.50M-60.44M-10.48M-72.43M-58.61M-91.14M
Operating Margin----69.89%---477.46%
EBITDA142.86K-68.21M-70.03M-10.46M-70.13M-49.71M-81.34M
EBITDA Margin----69.71%---426.12%
Net Income-109.00K-68.37M-70.76M-10.81M-69.97M-49.77M-82.13M
Net Income Margin----72.07%---430.25%
R&D-9.12M37.93M21.13M59.50M29.80M18.67M
R&D as % of Total Revenue---140.83%--97.81%
Interest Expense80.00K40.00K-----

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.00K22.56M18.34M46.95M70.38M215.30M305.88M
Total Liabilities2.22M32.36M32.55M71.12M163.09M11.22M21.54M
Total Equity-2.22M-9.80M-14.21M-24.17M-92.71M204.08M284.34M
Cash6.00K19.82M18.31M44.44M35.14M20.16M25.18M
Total Debt2.21M--250.00K329.00K1.38M815.00K
Net Debt2.20M-19.82M-18.31M-44.19M-34.81M-18.78M-24.36M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-19.00K-8.72M-52.85M-87.98M-60.38M-59.39M-69.17M
Investing Cash Flow--1.54M-5.74M-241.86M-29.62M-154.48M-75.67M
Financing Cash Flow-30.08M417.47M597.00K80.70M199.00M149.75M
Capital Expenditure01.54M5.74M6.59M30.00K468.00K827.00K
Free Cash Flow-19.00K-10.27M-58.59M-94.57M-60.41M-59.86M-70.00M
FCF to OCF100.00%117.72%110.86%107.49%100.05%100.79%101.20%

Earnings

Report DateJun 2, 2021Aug 12, 2021Nov 10, 2021Mar 21, 2022May 12, 2022Aug 11, 2022Nov 9, 2022Mar 20, 2023May 11, 2023Sep 11, 2023Nov 8, 2023Feb 27, 2024May 8, 2024Aug 14, 2024Nov 6, 2024Mar 19, 2025May 7, 2025Jul 30, 2025Nov 5, 2025Mar 24, 2026Mar 31, 2026Aug 11, 2026Nov 4, 2026
EPS Estimate0.00-0.29-0.28-0.30-0.39-0.49-0.44-0.49-0.40-0.97-0.24-0.13-0.82-0.67-0.43-0.42-0.32-0.54-0.67-0.92-1.07-1.21-1.01
EPS Actual-0.34-24.15-0.06-2.45-3.36-3.36-3.15-3.08-3.01-6.79-0.24-0.40-3.53-0.40-0.38-0.46-0.53-0.53-0.59-1.16-1.32-1.02-
Surprise--8227.59%78.32%-723.53%-761.54%-583.90%-608.98%-524.11%-660.68%-600.00%0.00%-207.69%-330.49%40.30%11.63%-9.52%-65.63%1.85%11.94%-26.09%-23.31%15.70%-
Timing-----------After-hoursAfter-hoursAfter-hoursPre-market-After-hoursPre-marketPre-marketPre-market-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap124.42M
Enterprise Value-101.29M
Trailing P/E0.00
Forward P/E0.00
Price / Sales5.79
Price / Book0.54
EPS-4.18
Book Value6.98
Revenue (TTM)21.48M
Gross Profit (TTM)19.70M
EBITDA-135.20M
Profit Margin0.00%
Operating Margin-622.90%
Return on Equity-59.21%
Return on Assets-37.36%
Shares Outstanding31.42M
Shares Float18.39M
Beta1.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 24.00
  • Strong Buy
    5
  • Buy
    3

Ownership Breakdown

Institutions
111.80%
Insiders
2.65%
Retail / Other
0.00%

Top Institutional Holders

  • RA Capital Management, LLC
    4.18M13.30%
  • Alpha Wave Global LP
    3.61M11.50%
  • FMR Inc
    3.60M11.45%
  • Versant Venture Management LLC
    2.66M8.46%
  • BlackRock Inc
    1.98M6.29%
  • Aberdeen Group PLC
    1.55M4.93%
  • Millennium Management LLC
    1.51M4.80%
  • Squarepoint Ops LLC
    1.51M4.79%
  • Franklin Templeton Inc
    1.10M3.50%
  • Vanguard Capital Management, LLC
    1.04M3.31%
  • 72 Investment Holdings, LLC
    1.02M3.24%
  • Blue Owl Capital Holdings LP
    756.72K2.41%
  • CAM Group Holding A/S
    700.00K2.23%
  • Morgan Stanley - Brokerage Accounts
    648.85K2.07%
  • Bank of America Corp
    547.53K1.74%
  • Geode Capital Management, LLC
    524.57K1.67%

Top Fund Holders

  • Fidelity Growth Company Fund
    889.22K2.83%
  • Vanguard MStar Total Stk Mkt Idx Invest
    819.61K2.61%
  • C WorldWide Healthcare Select 1A
    700.00K2.23%
  • iShares Russell 2000 ETF
    530.63K1.69%

Dividends

20241×
7.21Mar 22, 2024

Stock Splits

  • Mar 22, 20241:7